Novak Djokovic holds major stake in firm making drug to combat COVID-19

Novak Djokovic holds major stake in firm making drug to combat COVID-19

Serbian tennis star Novak Djokovic, recently deported from Australia due to his coronavirus vaccine status, is co-founder and majority shareholder of a biotech firm developing a COVID-19 treatment, the Danish company’s CEO said Wednesday.

“He is one of the founders of my company we founded in June 2020,” Ivan Loncarevic, the chief executive of QuantBioRes, said.

According to information publicly available in the Danish business register, Djokovic and his wife, Jelena, together hold a stake of 80% in QuantBioRes, which employs a workforce of around 20 in Denmark, Slovenia, Australia and Britain.

“We aim to develop a new technology to fight viruses and resistant bacteria and we decided to use COVID as a showcase,” Loncarevic said.

“If we succeed with COVID, we will succeed with other viruses.”

QuantBioRes is planning to launch clinical trials in the UK in the summer, the CEO said.

The unvaccinated men’s world No. 1 flew out of Melbourne on Sunday after he failed in a last-gasp court bid to stay and play in the opening Grand Slam of the year, where he was targeting a record 21st major title.

His dramatic departure followed a protracted, high-stakes legal battle between the athlete and Australian authorities that cast a dark shadow over the tournament.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.



Source link